Incyte Corporation (0J9P.L)
USD 61.98
(-0.75%)
USD 61.98
(-0.75%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 62.97 Million USD | -47.94% |
| 2022 | 120.95 Million USD | 112.44% |
| 2021 | 56.93 Million USD | 58.28% |
| 2020 | 35.97 Million USD | 117.95% |
| 2019 | 16.5 Million USD | 58.63% |
| 2018 | 10.4 Million USD | 60.52% |
| 2017 | 6.48 Million USD | 57.87% |
| 2016 | 4.1 Million USD | 130.29% |
| 2015 | 1.78 Million USD | 398.04% |
| 2014 | 358 Thousand USD | -11.82% |
| 2013 | 406 Thousand USD | 46.04% |
| 2012 | 278 Thousand USD | -92.14% |
| 2011 | 3.53 Million USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | -100.0% |
| 2004 | 7.14 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 63.64 Million USD | 1.06% |
| 2024 Q3 | 70.44 Million USD | -30.05% |
| 2024 Q2 | 100.7 Million USD | 58.24% |
| 2023 Q3 | 199.28 Million USD | 454.54% |
| 2023 Q2 | 35.93 Million USD | -77.19% |
| 2023 Q1 | 157.56 Million USD | 30.26% |
| 2023 FY | 62.97 Million USD | -47.94% |
| 2023 Q4 | 62.97 Million USD | -68.4% |
| 2022 Q2 | 94.12 Million USD | 32.87% |
| 2022 Q1 | 70.84 Million USD | 24.42% |
| 2022 FY | 120.95 Million USD | 112.44% |
| 2022 Q4 | 120.95 Million USD | 163.71% |
| 2022 Q3 | 45.86 Million USD | -51.27% |
| 2021 Q3 | 21.3 Million USD | 27.75% |
| 2021 Q4 | 56.93 Million USD | 167.28% |
| 2021 FY | 56.93 Million USD | 58.28% |
| 2021 Q1 | 40.37 Million USD | 12.25% |
| 2021 Q2 | 16.67 Million USD | -58.7% |
| 2020 FY | 35.97 Million USD | 117.95% |
| 2020 Q1 | 13.97 Million USD | -15.32% |
| 2020 Q2 | 16.33 Million USD | 16.87% |
| 2020 Q3 | 17.01 Million USD | 4.14% |
| 2020 Q4 | 35.97 Million USD | 111.46% |
| 2019 Q3 | 13.31 Million USD | 104.04% |
| 2019 Q4 | 16.5 Million USD | 23.93% |
| 2019 FY | 16.5 Million USD | 58.63% |
| 2019 Q1 | 11 Million USD | 5.77% |
| 2019 Q2 | 6.52 Million USD | -40.69% |
| 2018 Q4 | 10.4 Million USD | 73.62% |
| 2018 FY | 10.4 Million USD | 60.52% |
| 2018 Q1 | 4.63 Million USD | -28.54% |
| 2018 Q2 | 5.86 Million USD | 26.71% |
| 2018 Q3 | 5.99 Million USD | 2.11% |
| 2017 Q1 | 3.96 Million USD | -3.53% |
| 2017 FY | 6.48 Million USD | 57.87% |
| 2017 Q4 | 6.48 Million USD | 98.77% |
| 2017 Q3 | 3.26 Million USD | 11.3% |
| 2017 Q2 | 2.93 Million USD | -26.03% |
| 2016 FY | 4.1 Million USD | 130.29% |
| 2016 Q1 | 1.3 Million USD | -26.58% |
| 2016 Q4 | 4.1 Million USD | 0.69% |
| 2016 Q3 | 4.07 Million USD | -33.41% |
| 2016 Q2 | 6.12 Million USD | 367.84% |
| 2015 Q2 | 1.89 Million USD | -21.42% |
| 2015 FY | 1.78 Million USD | 398.04% |
| 2015 Q4 | 1.78 Million USD | -26.57% |
| 2015 Q1 | 2.41 Million USD | 574.3% |
| 2015 Q3 | 2.42 Million USD | 27.99% |
| 2014 Q2 | 269 Thousand USD | -22.48% |
| 2014 Q4 | 358 Thousand USD | -10.95% |
| 2014 Q1 | 347 Thousand USD | -14.53% |
| 2014 Q3 | 402 Thousand USD | 49.44% |
| 2014 FY | 358 Thousand USD | -11.82% |
| 2013 Q4 | 406 Thousand USD | 13.09% |
| 2013 FY | 406 Thousand USD | 46.04% |
| 2013 Q1 | 189 Thousand USD | -32.01% |
| 2013 Q2 | 133 Thousand USD | -29.63% |
| 2013 Q3 | 359 Thousand USD | 169.92% |
| 2012 Q4 | 278 Thousand USD | 46.32% |
| 2012 FY | 278 Thousand USD | -92.14% |
| 2012 Q1 | 3.51 Million USD | -0.65% |
| 2012 Q2 | 188 Thousand USD | -94.65% |
| 2012 Q3 | 190 Thousand USD | 1.06% |
| 2011 Q2 | - USD | 0.0% |
| 2011 FY | 3.53 Million USD | 0.0% |
| 2011 Q4 | 3.53 Million USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2005 FY | - USD | -100.0% |
| 2005 Q1 | - USD | -100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2004 FY | 7.14 Million USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | 7.14 Million USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -423.719% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -230.111% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -5.488% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -548.795% |
| bluebird bio, Inc. | 22.91 Million USD | -174.759% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -2132.258% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 83.68% |
| Myriad Genetics, Inc. | 20.1 Million USD | -213.294% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -64.418% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 18.649% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.243% |
| Waters Corporation | 516.23 Million USD | 87.802% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.762% |
| Biogen Inc. | 2.52 Billion USD | 97.508% |
| Nektar Therapeutics | 16.1 Million USD | -291.106% |
| Perrigo Company plc | 1.14 Billion USD | 94.48% |
| Dynavax Technologies Corporation | 53.29 Million USD | -18.169% |
| Illumina, Inc. | 587 Million USD | 89.272% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -507.135% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -49.542% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 94.312% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -472.577% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.56% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 4.04% |
| FibroGen, Inc. | 41.56 Million USD | -51.502% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 93.892% |
| OPKO Health, Inc. | 65.69 Million USD | 4.148% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 29.361% |
| Exelixis, Inc. | 17.32 Million USD | -263.517% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 97.544% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -316.069% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 2676.596% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 91.476% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -121.537% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 80.496% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -714.644% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 50.649% |
| Blueprint Medicines Corporation | 21.22 Million USD | -196.716% |
| Insmed Incorporated | 83.24 Million USD | 24.356% |
| TG Therapeutics, Inc. | 39.82 Million USD | -58.13% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 80.854% |